Lack of effect of desglycinamide-arginine-vasopressin (DGAVP) on memory in patients with korsakoff's syndrome.
The effect of desglycinamide9-[Arg8]-vasopressin (DGAVP) on memory processes was studied in patients with Korsakoff's syndrome. Intranasal treatment with DGAVP for 7 days affected neither attention nor short- and long-term memories. It is suggested that treatment with DGAVP is not indicated for all types of memory disorders, and that the beneficial effect of this treatment may depend on the integrity of certain brain structures.
D000368:Aged; D000425:Alcohol Amnestic Disorder / Q000188:drug therapy*; D001127:Arginine Vasopressin / Q000031:analogs & derivatives* / Q000627:therapeutic use; D001288:Attention / Q000187:drug effects; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D008297:Male; D008568:Memory / Q000187:drug effects*; D008875:Middle Aged
D001127:Arginine Vasopressin; C015119:argipressin, des-GlyNH2(9)-